Get started

2019

Singapore COVID-19 Wave 3 UpdateSo... Technical analysis is not the orthodox tool for Pandemic infection monitoring, BUT it appears that IF we can look beyond the box, we can see more, and get ahead of the curve a little more. This is the SECOND time the Singapore COVID-19 charts are giving us about 6-8 weeks heads up of an imminent spike in COVID-19 cases. Much could have been done IF we looked closer and took appropriate actions. Last post on this matter, on 5th March, it was clear and present danger that a 3rd wave spike was to happen in April... and now, we are in the onset of a spike in cases in Singapore. It should be about another 8 weeks before things we under control... This is NOT chance, but high probability (though unusual) projection of the dynamics. You see, the RPM in the middle panel shows that it is not as powerful a run up this time (as previously expected); and the MACD histograms correctly warned of this imminent spike, now indicating that it is probably nearing a peak out. This predictive model also works for other countries. So it is robust. Till next time, stay safe and stay healthy! PS... see related ideas below for the historical tracking
C
by Auguraltrader
ECB meeting in spotlightEUR/USD is having a rare day in negative territory. Currently, the pair is trading at 1.2006, down 0.24% on the day. The euro has been in fine form in April, racking up gains of 2.3%. The currency has made up most of the ground lost in March when EUR/USD fell by 2.8%. The direction of the US dollar has, to a large degree, been dependent on 10-year US Treasury yields. In March, yields moved higher and provided the dollar with a lift. Conversely, with yields retreating in April, the dollar has suffered broad losses. The ECB holds its policy meeting on Thursday (11:45 GMT), and the central bank is widely expected to hold the course on monetary policy and leave the main financing rate at 0.00%. With the developed economies expected to show significant recovery in 2021, there have been rising concerns about taper tantrums, once central banks change their ultra-accommodative stance, which has been put in place in order to deal with the severe economic downturn caused by the Covid-19 pandemic. This is unlikely to be an issue with the ECB, which appears determined to continue fiscal and monetary support for the eurozone until the recovery is well underway. Once that occurs, the ECB can be expected to reduce purchases under its emergency pandemic programme (PSPP), while continuing its traditional QE programme, under which the ECB has been purchasing bonds in the amount of EUR 20 billion/month throughout the Covid pandemic. With the upcoming ECB meeting expected to be a"snoozer", the meeting could well be a non-event for the euro. It has been a good week for the euro, which punched past the symbolic 1.20 level this week for the first time since March 4th. The currency could get a bit of a boost if ECB President Christine Lagarde's comments after the meeting are more optimistic than expected. EUR/USD is testing resistance at 1.2027. Above, there is resistance at 1.2073. On the downside, there is support at 1.1903 and 1.1825
by OANDA
Has CAD run out of gas?The Canadian dollar has reversed directions on Thursday. Currently, USD/CAD is trading at 1.2577, up 0.13% on the day. Since the start of 2021, the Canadian dollar is up about one percent against its US cousin, but there are signs that the currency may have touched bottom. The province of Ontario, the largest in Canada, is expected to announce an expansion of lockdown restrictions throughout the province. Ontario is expected to announce that the lockdown will be in force for 28 days, in a bid to curb soaring Covid rates. Canada's number of Covid cases has doubled compared to the beginning of March, but the vaccine rollout has been very slow, with only 2% of the population fully vaccinated. Another factor is the oil prices hit their most recent peak on March 5th and have been on the decline, even with the spike due to the Suez Canal closing. The unexpectedly strong GDP gave the Canadian dollar a boost on Wednesday, but the negative impact of Covid on the economy and falling oil prices could mean a bumpy road ahead for the Canadian dollar. Will US Nonfarm Payrolls crush the consensus?  The ADP Employment report for February came in at 517 thousand, shy of the estimate of 552 thousand but a huge rise from the previous read of 117 thousand. We'll get a look at official employment numbers on Friday, with nonfarm payrolls the highlight (12:30 GMT). The street consensus stands at 652 thousand, which would be a sharp rise from the January read of 379 thousand. However, given the impressive US recovery and an aggressive vaccine rollout, NFP could outperform by a wide margin. Barclays Bank sent a note with a forecast of 900 thousand, and some analysts are predicting a gain of above the one-million mark. If NFP is unexpectedly strong, we can expect some volatility from USD/CAD on Friday. 1.2641 has some breathing room in resistance after USD/CAD dropped considerably on Wednesday. This is followed by resistance at 1.2713. On the downside, there is support at 1.2486, followed by a support level is at 1.2403. Below, 1.2365 is both the 1-month low and the 52-week low.
by OANDA
Dyadic and Medytox To Develop Vaccines Against COVID-19 VariantsDyadic and Medytox To Develop Vaccines Against COVID-19 Variants Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g., tetravalent or quadrivalent COVID-19 vaccines) Exclusive license for Republic of Korea and multiple Southeast Asian countries, if successful Manufacturing protocols to produce vaccines from C1 have been successfully transferred and reproduced at Medytox finance.yahoo.com
NASDAQ:DYAI
by AlenCiken
$SPCB Wins COVID-19 Quarantine Project $3 Million per MonthSuperCom Wins COVID-19 Quarantine Compliance Project with the Israeli Government Valued at an Estimated $3 Million per Month in Recurring Revenues Initial project term of 3 months, with potential extension for up to 36 months This nationwide project is expected to commence next week, along with contract signing, for an initial term of 3 months, with an option to be extended for up to 36 months. The project is billed at a per-unit per-day rate is expected to generate approximately $3 million per month in recurring revenues for SuperCom. However, revenue may increase or decrease based on actual usage. finance.yahoo.com
NASDAQ:SPCB
by AlenCiken
Brent crude soars on OPEC surpriseThursday's OPEC+ meeting became a market-mover event, as members announced that production cuts would be extended in April. This caught the market completely off guard, as OPEC+ was widely expected to raise output by 500,000 barrels per month. Instead, OPEC+ has opted to hold back some 9.2 million barrels from the market each day, until at least the beginning of May. Crude responded to the OPEC+ announcement with sharp gains. Brent crude jumped 4.84% on Thursday, its highest one-day gain in two weeks. With an additional gain of close to 1 percent on Friday, Brent crude punched above the USD 68 line for the first time since January 2020. Oil prices have soared since November 2020, with Brent crude jumping a staggering 76% during that time. The key question now for investors and traders is whether the uptrend will continue, or will we see a levelling off in oil prices. The fact that the global economy is slowly recovering from Covid-19 should translate into higher demand for crude and maintain upward pressure on oil prices. At the same time, OPEC members are notorious for not abiding by production limits, which could put a curb on higher prices. In other news on the crude oil front, the EIA Crude Oil inventories report showed a record-high surplus of 21.6 million barrels. However, this figure was distorted by the recent Texas storm, which resulted in huge stockpiles due to refiners being unable to take on crude shipments. Prior to today's EIA release, nine of the past 11 readings have shown drawdowns, and with significant pent-up demand in the US economy, this trend could well continue. Brent crude has broken above resistance at the overnight high of 67.72 and double top, with the next resistance at 71.52, which has held since May 2019. Support is distant between USD62.03 and USD62.48.
FX_IDC:USDBRO
by OANDA
Strong pan-coronavirus effectiveness of clinical drug candidatesPan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application $NNVC reported yesterday on the strong pan-coronavirus effectiveness of its two COVID-19 clinical drug candidates for which the Company is preparing a pre-IND application. NV-CoV-2 is the Company's broad-spectrum anti-coronavirus clinical lead drug candidate for the treatment of COVID-19 patients based on its nanoviricides® platform. $NNVC is also developing NV-CoV-2-R, a drug treatment that combines the power of both NV-CoV-2 and remdesivir in a single drug that encapsulates and protects remdesivir inside NV-CoV-2. Both NV-CoV-2 and NV-CoV-2-R are expected to work against most, if not all , coronaviruses and their variants, based on the Company's findings on their pre-clinical effectiveness discussed below. NV-CoV-2 and NV-CoV-2-R were found to be highly effective in comparison to remdesivir against two distinctly different coronaviruses in our new cell culture studies leading towards a pre-IND application and thereafter an IND submission for these COVID-19 drug candidates. The Company intends to report on the results of these studies in its pre-IND application to the US FDA to obtain guidance regarding human clinical trials for treatment of COVID-19 patients. Additionally, the Company is actively seeking opportunities to engage appropriate sites for human clinical trials. Further, the Company is engaged in the preparation of clinical trial protocols and other activities that would be necessary for submitting an IND application to the US FDA. The Company has developed NV-CoV-2 based on its platform nanoviricides® technology. This approach enables rapid development of new drugs against a number of different viruses. finance.yahoo.com
AMEX:NNVC
by AlenCiken
2
Reduced recovery time in mild-to-moderate COVID-19 patientsNew Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients New Phase 3 study results show added nutritional protocol reduces recovery time in mild-to-moderate COVID-19 patients The addition of the nutritional protocol, or combined metabolic activators (CMA), to the Turkish standard of care not only reduced recovery time but improved liver health and decreased levels of inflammatory markers. finance.yahoo.com
NASDAQ:CDXC
by AlenCiken
Covid-19 vacine should be of benefit, Gold 4hr and daily Nice>>>Gold showing signs of a more dominant progress north, to really understand where I am going with this, you need to view my previous charts linked below. I at first seen a possible break north in the early new year, this started as planned, alas the new variant came and further decline progressed, I outlined this possible drop in my previous charts, but did not have my fingers crossed long enough. That said the yellow metal did show signs of weakening further, but much over the last few weeks has seen confidence become more apparent, this in part is due to an effective vaccine, less restrictions globally as lock downs become less restrictive, however gold does have a tendency to follow its own path and other strategies have gone in producing this idea, fractal method, fib and others. Note I did change the idea between the 4hr and daily in its path north. Areas to look for 1828,1858,1900,1928,1958 and 2015 For further information on this idea please PM me
OANDA:XAUUSDLong
by JohnLiv
Why $IFMK Skyrocketed in February? indoor dining shutdownsWhy $IFMK Skyrocketed in February There does not appear to be any direct news from the company. But it seems like that there was some coordination by day traders on social media. $IFMK shares were buoyed — thanks to discussions and speculation on Twitter and Twitter hashtags at the start of the month. iFresh Inc is an Asian/Chinese grocery supermarket chain in the North-Eastern U.S. providing food and other merchandise hard to find in mainstream grocery stores. The company generates a majority of its revenue from its retail segment. The other positive factor for the $IFMK is the surging Food delivery in NYC as indoor dining shutdowns continue (based out of nyc), due to covid 19. www.benzinga.com twitter.com
I
by AlenCiken
OCGN - how to play the COVAXIN news !OCGN: What do they do: mainly focus on developing eye disease therapy. they stepped into the Covid vaccine play and they have a strong product coming – COVAXIN –get this : vaccine can be at room temperature that is huge! transporting and storing with cooling can triple the costs and Pfizer’s vaccine has to be in cooling conditions and if I am not mistaken – double-check me on it – except AstraZeneca all of them need cooling. The vaccine of Ocugen is in cooperation with Bharat Biotech. the vaccine is supposed to be stronger against different strains of covid that are emerging …. The reason for all the noise is in the fine print -they closed a damn good deal on the sales in the U.S – they will receive 45% of profits with no upfront payment (someone was drunk when he agreed to that deal LOL)… so price target given by Roth Capital is 8$ -don’t agree – I think in the next year if all goes well this stock is above 15$ if we factor in the “meme” market going on could be much more and much faster but let's stay conservative. Ok lets talk shop – technical: POC (point of control) is not good – 3,18 but I am certain it will rise in the upcoming week – remember POC is like a “magnet” it will attract the price to it for obvious reason. Volume: average volume is 63M, last 2 days trading above 100M. 50% line of retracement is 3.95 (round it up to the 4$ area – its always areas not specific numbers ) which means we will need to see the golden number getting touched sooner or later (again consider “meme” market conditions are extremely abnormal) 4.5$ -6$ needs to be retested – there needs to be a retracement to that area with some sideways trend before we can say let’s see 8$ - in normal market conditions…. Notice on the chart the yellow square showing ling upper wicks meaning buying power got very weak – matches the volume orders on the left (the colors are somewhat faded meaning it needs accumulation), reversal signal. The red box in the lower part of the chart is the forbidden zone – it is the other side of the POC and the stock flew through that price too quick so if we see a pullback to the POC line we may see a sell-off to that area- don’t believe this will happen so soon as sentiment is very high Bottom line – I think we need to see some pull back the upcoming days before the stock goes higher to the next level of 7$-usually happens after a 2-3 days rally and once that is done we can target 7$+. Please keep in mind we are trading on a very speculative market and everything is highly inflated along with 1.9T $ coming and meme trend this is a very risky market and using my analysis on it can mean shit because it is NOT BEHAVING like it should at all !! FDGT will wait for a pullback before entering as the trend doesn’t look healthy This is not a recommendation of any sort Trader safe and be safe – we are the traders union and we trade by our own rules!
NASDAQ:OCGNLong
by FDGT_academy
OCGN and Bharat Biote Announce Execution of Definitive AgreementOcugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market. Definitive Agreement provides details of the previously announced intent to co-develop COVAXIN™ for the US market. Ocugen and Bharat Biotech to share US commercialization profits. Ocugen to receive initial supply of COVAXIN™ doses from Bharat Biotech upon authorization from US regulatory authorities while it ramps up manufacturing in the US. COVAXIN™ received EUA (Emergency Use Authorization) in India in January and is currently in a fully enrolled Phase 3 clinical trial involving 25,800 patients. COVAXIN™ (whole-virion inactivated COVID-19 vaccine candidate) effectively neutralizes UK variant of SARS-Cov-2 reducing the possibility of mutant virus escape. today announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s COVAXIN™ , an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market. Ocugen will have US rights to the vaccine candidate and will be responsible for clinical development , regulatory approval (including EUA) and commercialization for the US market . B harat Biotech will supply initial dose s to be used in the US upon Ocugen’s receipt of an EUA. In addition, Bharat Biotech will support the technology transfer for manufacturing in the US . In consideration for the exclusive license to the US market, Ocugen will share the profits from the sale of COVAXIN™ in the US market with Bharat Biotech, with Ocugen retaining 45% of the profits. In preparation for the development of COVAXIN™ in the US, Ocugen’s Vaccine Scientific Advisory Board and Ocugen management have initiated discussions with the U.S. Food & Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (BARDA) to develop a regulatory path to EUA and, eventually, biologics license application (BLA) approval in the US market for COVAXIN™. Ocugen is also in active discussions with manufacturers in the US to produce a significant number of doses of COVAXIN™ to support its US immunization program. H.C. Wainwright analyst Swayampakula Ramakanth raised his rating on Ocugen's stock on Thursday from neutral to buy and placed a $4.50 price forecast on its shares. Ramakanth cheered Ocugen's recent deal with India-based vaccine developer Bharat Biotech to potentially bring Covaxin, a COVID-19 vaccine candidate, to the U.S. market. Ramakanth posits that Covaxin could induce broader immunity and better protection against new coronavirus strains than the COVID-19 vaccines that have received emergency use authorization in the U.S. He also highlighted Covaxin's potential logistical advantages, due to its less onerous temperature storage requirements. Roth Capital analyst Zegbeh Jallah, meanwhile, believes Ocugen's share price could rise to as high as $8. Jallah applauded the structure of the deal, which gave Ocugen a 45% share of the potential profits from Covaxin's U.S. sales without requiring it to make an upfront payment to Bharat Biotech . Jallah's price target represents potential gains for investors of roughly 52% from Ocugen's closing price on Friday. Much of Ocugen's future growth prospects now rest on its ability to obtain emergency use authorization for Covaxin in the U.S . Thus, investors should brace for volatility in Ocugen's stock price as it advances toward clinical trials.
NASDAQ:OCGN
by AlenCiken
4
Lexaria Provides Guidance on Upcoming R&DLexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering Lexaria also announced the pricing of an underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The shares of common stock and warrants comprising the units are immediately separable and will be issued separately, but will be purchased together. The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. The Company has granted the underwriter a 30-day option to purchase up to an additional 274,285 shares of common stock and/or warrants to purchase up to 274,285 shares of common stock. finance.yahoo.com Lexaria Provides Guidance on Upcoming R&D Lexaria recently closed an oversubscribed financing of US$11 million that has greatly enhanced the Company's ability to conduct applied R&D designed to evidence effectiveness of its patented DehydraTECHTM drug delivery technology across multiple classes of bioactive substances or drugs. In the weeks to come, Lexaria expects to announce many new studies designed to provide initial evidence expected to support further study and commercial exploitation. All studies referenced within this press release are fully funded from existing Company resources. finance.yahoo.com
NASDAQ:LEXX
by AlenCiken
TYME Granted U.S. Patent Claims Treat COVID-19 InfectionsTYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections TYME announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating COVID-19. Unlike immune therapies that depend upon the structure of the external virus coat of COVID-19 where the therapy directs its attack, we believe TYME-19 is agnostic to this structure and any mutations to the viral coat. TYME intends to initiate the appropriate clinical trials to substantiate the safety and efficacy of TYME-19. TYME-19 is an investigational compound that is not approved in the U.S. for any disease indication. finance.yahoo.com
T
by AlenCiken
1